Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ET

Company Participants

Alex Braun - Head IR

Daniel O'Connell - President and Chief Executive Officer

Eric Siemers - , Chief Medical Officer

Matt Zuga - Chief Financial Officer and Chief Business Office

Conference Call Participants

Paul Matteis - Stifel

Tom Shrader - BTIG

Judah Frommer - Credit Suisse

Operator

Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2022 Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Alex Braun, Head of Investor Relations. Please go ahead.

Alex Braun

Thank you, Michelle. Good morning, and welcome to the Acumen conference call to discuss our business update and financial results for the year ended December 31, 2022. With me today are Dan O'Connell, our Chief Executive Officer; Dr. Eric Siemers, our Chief Medical Officer; and Matt Zuga, our Chief Financial Officer and Chief Business Officer.

Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find our press release issued this morning and a related slide presentation that we'll discuss today. Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws, including statements concerning our financial outlook and expected business plans. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Please see Slide 2 of the accompanying presentation, our press release issued this morning and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments. After our prepared remarks, we will open the call for Q&A.

Now I'll turn the call over to Dan.

Daniel O'Connell

Thank you, Alex. Good morning, and thank you, everyone, for joining us today. 2022 was a pivotal year for Acumen marked by significant progress advancing the critical development of ACU193, the first monoclonal antibody tested in Alzheimer's patients that was discovered and developed to selectively target soluble amyloid beta oligomers.